Home  /  Resource Library  /  Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma – an open-label, multicentre phase I/II study (DSHNHL-R6)

Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma – an open-label, multicentre phase I/II study (DSHNHL-R6)

Results of a study investigating lenalidomide in combination with chemoimmunotherapy for treatment of relapsed large cell lymphomas.